hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06294587, orgStudyIdInfo id: IRB-300012407, briefTitle: Evaluation of Free Gingival Graft Timing, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2026-07, completionDateStruct date: 2027-07, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-03-05, sponsorCollaboratorsModule leadSponsor name: University of Alabama at Birmingham, class: OTHER, descriptionModule briefSummary: This clinical trial aims to compare and evaluate the clinical outcomes between two distinct treatment sequences: free gingival graft surgery preceding guided bone regeneration and guided bone regeneration followed by free gingival graft., conditionsModule conditions: Ridge Augmentation, conditions: Alveolar Mucosa, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: FGG Before GBR, interventions name: FGG after GBR, outcomesModule primaryOutcomes measure: Volumetric outcome assessment, primaryOutcomes measure: Buccal soft tissue profile, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Unversity of Alabama at Birmingham, School of Dentistry, city: Birmingham, state: Alabama, zip: 35294-0007, country: United States, contacts name: Hussein Basma, DDS, MS, role: CONTACT, phone: 205-975-2888, email: basma86@uab.edu, contacts name: Sarah Startley, DMD, role: CONTACT, phone: 205-975-8711, email: ss1971@uab.edu, contacts name: Hussein Basma, DDS, MS, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 33.52066, lon: -86.80249, hasResults: False
protocolSection identificationModule nctId: NCT06294574, orgStudyIdInfo id: 300011943, briefTitle: Improved Successful Retrieval Rate of HydroMARK Plus Breast Biopsy Site Marker in Comparison to HydroMARK as Well as Improved Surgeon Satisfaction, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-12, primaryCompletionDateStruct date: 2026-12, completionDateStruct date: 2026-12, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-03-29, sponsorCollaboratorsModule leadSponsor name: University of Alabama at Birmingham, class: OTHER, collaborators name: Mammotome, descriptionModule briefSummary: The purpose of the study is to test how successful the retrieval rate of the new HydroMARK Plus Breast Biopsy Site Marker in comparison to HydroMARK., conditionsModule conditions: Breast Neoplasm, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: DIAGNOSTIC, maskingInfo masking: NONE, enrollmentInfo count: 150, type: ESTIMATED, armsInterventionsModule interventions name: HydroMARK Plus Clip, outcomesModule primaryOutcomes measure: Retrieval rate of the HydroMARK Plus clip., secondaryOutcomes measure: Level of satisfaction of the surgeon with the retrieval of the HydroMARK Plus clip., eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 90 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: The Kirklin Clinic, city: Birmingham, state: Alabama, zip: 35249, country: United States, contacts name: Quenteeria Mooney, role: CONTACT, phone: 205-996-1082, email: qmooney@uabmc.edu, contacts name: Ceren Yalniz, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 33.52066, lon: -86.80249, hasResults: False
protocolSection identificationModule nctId: NCT06294561, orgStudyIdInfo id: TGRX-326-1003, briefTitle: TGRX-326 Pharmacokinetic Drug Interaction, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-04, primaryCompletionDateStruct date: 2024-04-30, completionDateStruct date: 2024-06-30, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-03-08, sponsorCollaboratorsModule leadSponsor name: Shenzhen TargetRx, Inc., class: INDUSTRY, collaborators name: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, descriptionModule briefSummary: This is a drug-drug interaction study for TGRX-326 to evaluate the effects of CYP3A inhibitor/inducer drugs on pharmacokinetic profiles of TGRX-326, an ALK inhibitor indicated for treatment of Non-small cell lung cancer., conditionsModule conditions: Non Small Cell Lung Cancer, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 32, type: ESTIMATED, armsInterventionsModule interventions name: Itraconazole+TGRX-326, interventions name: Efavirenz+TGRX-326, outcomesModule primaryOutcomes measure: Plasma Tmax, primaryOutcomes measure: Plasma Cmax, primaryOutcomes measure: Plasma AUC(0-t), primaryOutcomes measure: Plasma AUC(0-inf), primaryOutcomes measure: T1/2, primaryOutcomes measure: Plasma volume of distribution (Vz/F), primaryOutcomes measure: Plasma clearance (CL/F), secondaryOutcomes measure: Adverse events/serious adverse events, secondaryOutcomes measure: Corrected QT Interval, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 45 Years, stdAges: ADULT, contactsLocationsModule locations facility: Nanjing Drug Tower Hospital, status: RECRUITING, city: Nanjing, state: Jiangsu, zip: 210008, country: China, contacts name: Juan Li, MD, role: CONTACT, phone: +862583105910, email: juanli2003@163.com, geoPoint lat: 32.06167, lon: 118.77778, hasResults: False
protocolSection identificationModule nctId: NCT06294548, orgStudyIdInfo id: IRB-300012272 (UAB 23152), briefTitle: A Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCC, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-31, primaryCompletionDateStruct date: 2027-05-31, completionDateStruct date: 2027-12-31, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: University of Alabama at Birmingham, class: OTHER, descriptionModule briefSummary: This is a phase Ib/II, dose escalation and dose expansion study of valemetostat (DS-3201) with atezolizumab and bevacizumab in patients advanced Hepatocellular carcinoma (HCC) who did not receive prior systemic therapy for advanced HCC., conditionsModule conditions: Hepatocellular Carcinoma, designModule studyType: INTERVENTIONAL, phases: PHASE1, phases: PHASE2, designInfo allocation: NON_RANDOMIZED, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 45, type: ESTIMATED, armsInterventionsModule interventions name: Valemetostat, interventions name: Atezolizumab, interventions name: Bevacizumab, outcomesModule primaryOutcomes measure: Phase 1b, primaryOutcomes measure: Phase II, secondaryOutcomes measure: Safety and pharmacokinetics (PK), secondaryOutcomes measure: Progression free survival (PFS), secondaryOutcomes measure: Overall survival (OS), secondaryOutcomes measure: Duration of response (DoR), secondaryOutcomes measure: Disease Control Rate (DCR), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University of Alabama at Birmingham, city: Birmingham, state: Alabama, zip: 35294, country: United States, contacts name: Margaret Thomas, MPH, role: CONTACT, email: margaretannthomas@uabmc.edu, contacts name: Mehmet S Akce, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 33.52066, lon: -86.80249, hasResults: False
protocolSection identificationModule nctId: NCT06294535, orgStudyIdInfo id: 2024, briefTitle: The Accuracy of Reconstruction of Orbital Walls Fracture Using Prebent Mesh Versus Patient Specific Implant, statusModule overallStatus: ENROLLING_BY_INVITATION, startDateStruct date: 2023-12-11, primaryCompletionDateStruct date: 2024-05-18, completionDateStruct date: 2024-06-06, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-03-19, sponsorCollaboratorsModule leadSponsor name: Tanta University, class: OTHER, descriptionModule briefSummary: under GA, incision to access to orbital walls. Then insertion of prebent titanium mesh or customized titanium implant and fixation with miniscrews, examination of ocular motility using forced duction test followed by closure of flap., conditionsModule conditions: Orbital Fractures, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, maskingDescription: patient select randomly from closed label, whoMasked: PARTICIPANT, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: reconstruction of orbital walls, outcomesModule primaryOutcomes measure: restoring the accurate position of eye, primaryOutcomes measure: motility of eye, primaryOutcomes measure: volume of orbit, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 55 Years, stdAges: ADULT, contactsLocationsModule locations facility: Faculty of Dentistry, Tanta University, city: Tanta, zip: 3111, country: Egypt, geoPoint lat: 30.78847, lon: 31.00192, hasResults: False
protocolSection identificationModule nctId: NCT06294522, orgStudyIdInfo id: 1984, briefTitle: Reconstruction of Nasal Floor for Three-dimensional Repair of Alveolar Cleft, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-07-20, primaryCompletionDateStruct date: 2024-01-06, completionDateStruct date: 2024-02-16, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-03-19, sponsorCollaboratorsModule leadSponsor name: Tanta University, class: OTHER, descriptionModule briefSummary: reconstruction of alveolar cleft with autogenous bone after elevation of mucoperiosteal flap and suturing of nasal floor and palatal flap, conditionsModule conditions: Alveolar Cleft, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 16, type: ACTUAL, armsInterventionsModule interventions name: reconstruction of alveolar cleft, outcomesModule primaryOutcomes measure: recurrence of oronasal fistula, primaryOutcomes measure: volume of alveolar cleft after reconstruction, primaryOutcomes measure: density of bone, eligibilityModule sex: ALL, minimumAge: 9 Years, maximumAge: 18 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule locations facility: Faculty of Dentistry, Tanta University, city: Tanta, zip: 3111, country: Egypt, geoPoint lat: 30.78847, lon: 31.00192, hasResults: False
protocolSection identificationModule nctId: NCT06294496, orgStudyIdInfo id: 2023YFS0274, briefTitle: Study of Carotid Artery Stenosis Through the Integration of Multimodal Imaging and Computational Fluid Dynamics, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-06-01, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-03-05, sponsorCollaboratorsModule leadSponsor name: Sichuan Provincial People's Hospital, class: OTHER, descriptionModule briefSummary: Ischemic stroke affects 2.5 to 3 million people annually in China, ranking as the leading cause of death and disability. Cervical artery stenosis is a significant contributor to this problem, with about 50% of patients experiencing cognitive impairment due to reduced cerebral blood flow. Two main surgical approaches, carotid endarterectomy (CEA) and carotid artery stenting (CAS), are used to treat severe cervical artery stenosis, but their effects on various factors remain unclear.This project collects multimodal imaging data, including CT perfusion and angiography, to create 3D models of cervical artery stenosis. Computational fluid dynamics and AI analysis are used to assess hemodynamics. By monitoring blood flow, oxygen levels, and evaluating postoperative outcomes, the goal is to tailor surgical approaches for better patient outcomes and improved quality of life., conditionsModule conditions: Carotid Stenosis, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: CEA/CAS, outcomesModule primaryOutcomes measure: Perioperative cardio-cerebrovascular adverse events, secondaryOutcomes measure: Compute fluid dynamics parameters, secondaryOutcomes measure: Clinical outcome, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Sichuan Provincial People's Hospital, status: RECRUITING, city: Chengdu, state: Sichuan, zip: 610072, country: China, contacts name: Li Xiong, Master, role: CONTACT, phone: 028-87393020, email: lcl1206778081@163.com, contacts name: Chaoqun Zeng, Ph.D., role: SUB_INVESTIGATOR, geoPoint lat: 30.66667, lon: 104.06667, hasResults: False
protocolSection identificationModule nctId: NCT06294483, orgStudyIdInfo id: Soh-Med-24-01-09MS, briefTitle: Comparison Between Early-onset and Late-onset Patients With Systemic Lupus Erythematosus., statusModule overallStatus: ENROLLING_BY_INVITATION, startDateStruct date: 2024-01-10, primaryCompletionDateStruct date: 2024-07-30, completionDateStruct date: 2024-08-30, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-03-05, sponsorCollaboratorsModule leadSponsor name: Sohag University, class: OTHER, descriptionModule briefSummary: The present study aims to:Compare clinical features, hematological indices and disease activity between the early-onset and late-onset patients with systemic lupus erythematosus.Evaluate the relationship between hematological indices (mean platelet volume, platelet lymphocyte ratio and neutrophil lymphocyte ratio) and Systemic lupus erythematosus (SLE) disease manifestations and activity., conditionsModule conditions: Systemic Lupus Erythematosus, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CROSSOVER, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: CBC, interventions name: Antinuclear Antibody tests (ANA), interventions name: Rest of ANA profile, interventions name: C3 and C4 complement level., interventions name: Anti phospholipid marker, interventions name: Serum creatinine and Alb/create ratio, interventions name: 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus., interventions name: SLEDAI scores, outcomesModule primaryOutcomes measure: Evaluate the hematological indices as (mean platelet volume) of our SLE patient., primaryOutcomes measure: Evaluate the hematological indices as (neutrophil lymphocyte ratio) of our SLE patient., primaryOutcomes measure: Evaluate the hematological indices ( platelet lymphocyte ratio ) of our SLE patient., primaryOutcomes measure: Compare the degree of disease activity between the early-onset and late-onset patients with systemic lupus erythematosus., primaryOutcomes measure: Evaluate the correlation between hematological indices (mean platelet volume, platelet lymphocyte ratio and neutrophil lymphocyte ratio) and Systemic lupus erythematosus (SLE) disease manifestations and activity., eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Sohag university hospital, city: Sohag, country: Egypt, geoPoint lat: 26.55695, lon: 31.69478, hasResults: False
protocolSection identificationModule nctId: NCT06294470, orgStudyIdInfo id: 01-2023, briefTitle: Efficacy of Stapled Hemorrhoidopexy for the Treatment of Obstructive Defecation Syndrome, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-05-01, primaryCompletionDateStruct date: 2023-11-30, completionDateStruct date: 2023-12-15, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-03-05, sponsorCollaboratorsModule leadSponsor name: Universidad Central de Venezuela, class: OTHER, descriptionModule briefSummary: The objective of this study is to assess the efficiency of the procedure for hemorrhoidal prolapse and pexia in alleviating symptoms of defecatory obstruction among patients with grade II to IV mucohemorrhoidal prolapse., conditionsModule conditions: Hemorrhoids, conditions: Defecation Disorder, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 34, type: ACTUAL, armsInterventionsModule interventions name: Ballon expulsion test, interventions name: Colonic transit time, interventions name: Stapled hemorrhodopexy, outcomesModule primaryOutcomes measure: Postoperative improvement of symptoms of defecatory obstruction, secondaryOutcomes measure: Postoperative change of the balloon expulsion test, secondaryOutcomes measure: Postoperative change of the colonic transit time, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Hospital Domingo Luciani, city: Caracas, state: Miranda, zip: 1073, country: Venezuela, geoPoint lat: 10.48801, lon: -66.87919, hasResults: False
protocolSection identificationModule nctId: NCT06294457, orgStudyIdInfo id: CI-2024-480, briefTitle: Effectiveness of Non-invasive Neuromodulation for Intestinal Transit in Healthy Subjects, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03, primaryCompletionDateStruct date: 2024-03, completionDateStruct date: 2024-06, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-03-05, sponsorCollaboratorsModule leadSponsor name: Universidad Europea de Madrid, class: OTHER, descriptionModule briefSummary: ObjectivesMain objective:Assess the effectiveness of non-invasive neuromodulation treatment (NESA) for the management of constipation in patients without diagnosed pathology in SpainSecondary objectives:Evaluate the improvement in sleep quality Analyze the improvement in blood pressure quality Measure the improvement in cortisol quality Determine if there is an improvement in heart rate, conditionsModule conditions: Constipation, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: DOUBLE, maskingDescription: The device will be placed with no current. This type of neuromodulation gives no feeling at all to the patient while administred, so there is no way for the patient to know if the apparatus is connected or not., whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: Non-Invasive Neuromodulation NESA, outcomesModule primaryOutcomes measure: Quality of life by constipation (CVE-20), secondaryOutcomes measure: Sleep Quality, secondaryOutcomes measure: Cardiac Frecuency, secondaryOutcomes measure: Arterial pressure, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06294431, orgStudyIdInfo id: RADX-P-2406, briefTitle: Radicle Clarity 24: A Study of Health and Wellness Products on Cognitive Function and Related Health Outcomes, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2024-02-22, primaryCompletionDateStruct date: 2024-05, completionDateStruct date: 2024-07, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-04-24, sponsorCollaboratorsModule leadSponsor name: Radicle Science, class: INDUSTRY, descriptionModule briefSummary: A randomized, double-blind, placebo-controlled direct-to-consumer study of health and wellness products on cognitive function and related health outcomes, conditionsModule conditions: Cognitive Function, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Participants will be stratified based on their gender assigned at birth and health outcome score during enrollment, then randomized to one of the study arms. Each participant will have an equal chance of being assigned to any study arm., primaryPurpose: OTHER, maskingInfo masking: DOUBLE, maskingDescription: The investigator is blinded to the participants' assigned study products. Participants are blinded to the study product they received., whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 1001, type: ESTIMATED, armsInterventionsModule interventions name: Placebo Control Form 1, interventions name: Clarity Active Study Product 1.1 Usage, interventions name: Placebo Control Form 2, interventions name: Clarity Active Study Product 2.1 Usage, outcomesModule primaryOutcomes measure: Change in cognitive function, secondaryOutcomes measure: Change in fatigue, secondaryOutcomes measure: Change in sleep-related impairment, secondaryOutcomes measure: Minimal clinical importance difference (MCID) in cognitive function, otherOutcomes measure: Change in mood (emotional distress-depression), otherOutcomes measure: Change in concentration of at-home (direct-to-consumer) specimen assays either saliva, blood or stool, eligibilityModule sex: ALL, minimumAge: 21 Years, maximumAge: 105 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Radicle Science, Inc, city: Del Mar, state: California, zip: 92014, country: United States, geoPoint lat: 32.95949, lon: -117.26531, hasResults: False
protocolSection identificationModule nctId: NCT06294418, orgStudyIdInfo id: 1-037-23, briefTitle: FCI in Post-operative Low Grade Gliomas, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-15, primaryCompletionDateStruct date: 2025-03, completionDateStruct date: 2025-03, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-03-05, sponsorCollaboratorsModule leadSponsor name: NHS Grampian, class: OTHER_GOV, collaborators name: University of Aberdeen, descriptionModule briefSummary: The aim of this pilot study is to explore the utility of a new imaging technique, called Field Cycling Imaging (FCI), in postoperative low grade gliomas.The main question it aims to answer is if FCI can differentiate subtypes of low grade gliomas. Participants will have one FCI scan., conditionsModule conditions: Glioma, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: BASIC_SCIENCE, maskingInfo masking: NONE, enrollmentInfo count: 10, type: ESTIMATED, armsInterventionsModule interventions name: Field Cycling Imaging (FCI), outcomesModule primaryOutcomes measure: Differentiation of sub-types of low grade glioma assessed by Field Cycling Imaging (FCI) T1 dispersion profiles, eligibilityModule sex: ALL, minimumAge: 16 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Aberdeen Royal Infirmary, status: RECRUITING, city: Aberdeen, zip: AB25 2ZD, country: United Kingdom, contacts name: Arnab K Rana, Dr, role: CONTACT, phone: +441224438363, email: arnab.rana@abdn.ac.uk, geoPoint lat: 57.14369, lon: -2.09814, hasResults: False